Litcius/Paper detail

Use of Upadacitinib in 16 Tofacitinib-refractory Ulcerative Colitis Patients: A Single-center Case 2Series

Jake Levine, Jey McKibbin, Rebecca Ham, Shirley Cohen‐Mekelburg, Shrinivas Bishu, Kevin Tang, Peter Higgins, Jeffrey Berinstein

2023Inflammatory Bowel Diseases19 citationsDOIOpen Access PDF

Abstract

Lay Summary We present a case series of 16 patients with ulcerative colitis who received upadacitinib after failing tofacitinib. Five patients (36%) achieved steroid-free clinical remission. Five (62%) demonstrated endoscopic response, while 2 patients (25%) achieved endoscopic remission. Adverse events were low.

Topics & Concepts

TofacitinibUlcerative colitisMedicineRefractory (planetary science)GastroenterologyInternal medicineRheumatoid arthritisDiseaseAstrobiologyPhysicsInflammatory Bowel DiseaseMicroscopic ColitisDiagnosis and treatment of tuberculosis
Use of Upadacitinib in 16 Tofacitinib-refractory Ulcerative Colitis Patients: A Single-center Case 2Series | Litcius